| P50 | author | Andrea Fagiolini | Q42651594 |
| | Benjamin I Goldstein | Q88048305 |
| P2093 | author name string | Arianna Goracci | |
| | Francesco Casamassima | |
| | Rocco Forgione | |
| | Wilmer Mostacciuolo | |
| P2860 | cites work | Clinical factors associated with treatment noncompliance in euthymic bipolar patients | Q28138392 |
| | Using drug claims data to assess the relationship of medication adherence with hospitalization and costs | Q30652843 |
| | Long-acting risperidone: a review of its role in the treatment of bipolar disorder | Q33886093 |
| | The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases | Q33963449 |
| | Akathisia: an updated review focusing on second-generation antipsychotics | Q34017194 |
| | Bipolar disorder therapeutics: maintenance treatment | Q34052830 |
| | Consensus development conference on antipsychotic drugs and obesity and diabetes | Q34293049 |
| | Current research on rapid cycling bipolar disorder and its treatment | Q34521351 |
| | Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). | Q34564599 |
| | Treatment non-adherence in affective disorders. | Q34592227 |
| | Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. | Q34742844 |
| | Enhancement of treatment adherence among patients with bipolar disorder | Q35682922 |
| | Long-term observational comparison of risperidone and olanzapine in bipolar disorder | Q35871009 |
| | Enhancing outcomes in patients with bipolar disorder: results from the Bipolar Disorder Center for Pennsylvanians Study | Q35992713 |
| | Risperidone for bipolar disorders | Q36106798 |
| | Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system | Q36115386 |
| | Identifying and improving non-adherence in bipolar disorders. | Q36286408 |
| | Long-acting risperidone: focus on safety | Q36544063 |
| | Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder | Q36708811 |
| | Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials | Q36778511 |
| | Medication adherence and the use of long-acting antipsychotics in bipolar disorder | Q36783862 |
| | Depot antipsychotic medications in bipolar disorder: a review of the literature | Q36905876 |
| | Risperidone long-acting injection: a review of its long term safety and efficacy | Q37062563 |
| | Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review | Q37111491 |
| | Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder | Q37152810 |
| | Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia | Q37162808 |
| | Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy | Q37169607 |
| | Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness | Q37356486 |
| | Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk | Q37546078 |
| | Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization | Q40623890 |
| | Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium | Q41640883 |
| | Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder | Q42641073 |
| | An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study | Q42657517 |
| | A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently | Q43239518 |
| | Antipsychotic-induced type 2 diabetes: evidence from a large health plan database | Q44288625 |
| | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics | Q44299750 |
| | Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic | Q44460085 |
| | Increased suicide attempt rate among patients interrupting use of atypical antipsychotics | Q44537255 |
| | Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. | Q44917863 |
| | Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics | Q44939960 |
| | Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia | Q44972411 |
| | Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol | Q45168624 |
| | Self-reported medication treatment adherence among veterans with bipolar disorder | Q45332886 |
| | Maintenance electroconvulsive therapy combined with long-acting risperidone in the treatment of resistant bipolar affective disorder. | Q46013557 |
| | Long-acting risperidone-induced periorbital edema | Q46244692 |
| | The long-term natural history of the weekly symptomatic status of bipolar I disorder | Q46317822 |
| | Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial | Q46416766 |
| | A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone | Q46495720 |
| | Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone | Q46525510 |
| | Long-acting risperidone in stable patients with schizoaffective disorder | Q46689239 |
| | Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients | Q46732807 |
| | Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone | Q46921502 |
| | A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone | Q46973159 |
| | Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients | Q48332281 |
| | Branch retinal artery occlusion after injection of a long-acting risperidone preparation. | Q50930956 |
| | Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. | Q51740194 |
| | Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study. | Q52921224 |
| | Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment | Q57612798 |
| | The Role of Parkinsonism and Antiparkinsonian Therapy in the Subsequent Development of Tardive Dyskinesia | Q58134786 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | risperidone | Q412443 |
| P304 | page(s) | 1727-1740 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder | |
| P478 | volume | 11 | |